Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study

OBJECTIVES: This study aimed to investigate the efficacy and safety of transarterial chemoembolization (TACE) plus camrelizumab, a monoclonal antibody targeting programmed death-1, and apatinib for patients with intermediate and advanced hepatocellular carcinoma (HCC) in a real-world setting. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Zhi-Cheng, Zhong, Bin-Yan, Chen, Jian-Jian, Zhu, Hai-Dong, Sun, Jun-Hui, Yin, Guo-Wen, Ge, Nai-Jian, Luo, Biao, Ding, Wen-Bin, Li, Wen-Hui, Chen, Li, Wang, Yu-Qing, Zhu, Xiao-Li, Yang, Wei-Zhu, Li, Hai-Liang, Teng, Gao-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Interventional
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667391/
https://www.ncbi.nlm.nih.gov/pubmed/37368105
http://dx.doi.org/10.1007/s00330-023-09754-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667391/
https://www.ncbi.nlm.nih.gov/pubmed/37368105
http://dx.doi.org/10.1007/s00330-023-09754-2

Ejemplares similares